Rifamycin Meets Endpoints in Diarrhea Trial

Italian drugmaker Cosmo Pharmaceuticals’ Rifamycin SV MMX achieved its endpoint of noninferiority versus Normix in a Phase II trial for the treatment of infectious diarrhea.

 

Rifamycin SV MMX also was found to be as safe and as tolerable as Normix, according to Cosmo.

Based on these results, the company is proceeding with preparations for Phase III trials, which it expects to begin in 2008.